JORGE CASTILLO to Signal Transduction
This is a "connection" page, showing publications JORGE CASTILLO has written about Signal Transduction.
Connection Strength
0.891
-
Genomic Landscape of Waldenstr?m Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):745-752.
Score: 0.254
-
Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer J. 2016 Jan-Feb; 22(1):34-9.
Score: 0.212
-
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 04; 95(4):435-445.
Score: 0.071
-
Genomic evolution of ibrutinib-resistant clones in Waldenstr?m macroglobulinaemia. Br J Haematol. 2020 06; 189(6):1165-1170.
Score: 0.071
-
Novel approaches to targeting MYD88 in Waldenstr?m macroglobulinemia. Expert Rev Hematol. 2017 08; 10(8):739-744.
Score: 0.059
-
Genomics, Signaling, and Treatment of Waldenstr?m Macroglobulinemia. J Clin Oncol. 2017 Mar 20; 35(9):994-1001.
Score: 0.057
-
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr?m macroglobulinaemia cells. Br J Haematol. 2015 Mar; 168(5):701-7.
Score: 0.049
-
Waldenstr?m macroglobulinemia. Hematol Oncol Clin North Am. 2014 Oct; 28(5):945-70.
Score: 0.048
-
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nat Rev Clin Oncol. 2024 Dec; 21(12):867-887.
Score: 0.024
-
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer J. 2020 01 31; 10(1):12.
Score: 0.018
-
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15; 23(10):2400-2404.
Score: 0.014
-
Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. Br J Haematol. 2017 06; 177(5):808-813.
Score: 0.014